3593 studies found for:    Open Studies | "Carcinoma"
Show Display Options
Rank Status Study
21 Recruiting AZD1775, Docetaxel, and Cisplatin Before Surgery in Treating Patients With Borderline Resectable Stage III-IVB Squamous Cell Carcinoma of the Head and Neck
Conditions: Stage III Laryngeal Squamous Cell Carcinoma;   Stage III Oral Cavity Squamous Cell Carcinoma;   Stage III Oropharyngeal Squamous Cell Carcinoma;   Stage IVA Laryngeal Squamous Cell Carcinoma;   Stage IVA Oral Cavity Squamous Cell Carcinoma;   Stage IVA Oropharyngeal Squamous Cell Carcinoma;   Stage IVB Laryngeal Squamous Cell Carcinoma;   Stage IVB Oral Cavity Squamous Cell Carcinoma;   Stage IVB Oropharyngeal Squamous Cell Carcinoma
Interventions: Drug: Cisplatin;   Drug: Docetaxel;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Procedure: Therapeutic Conventional Surgery;   Drug: WEE1 Inhibitor MK-1775
22 Recruiting Hsp90 Inhibitor AT13387 in Treating Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck Receiving Radiation Therapy and Cisplatin
Conditions: Human Papillomavirus Infection;   Stage IVA Hypopharyngeal Squamous Cell Carcinoma;   Stage IVA Laryngeal Squamous Cell Carcinoma;   Stage IVA Oral Cavity Squamous Cell Carcinoma;   Stage IVA Oropharyngeal Squamous Cell Carcinoma;   Stage IVB Hypopharyngeal Squamous Cell Carcinoma;   Stage IVB Laryngeal Squamous Cell Carcinoma;   Stage IVB Oral Cavity Squamous Cell Carcinoma;   Stage IVB Oropharyngeal Squamous Cell Carcinoma
Interventions: Drug: Cisplatin;   Drug: Hsp90 Inhibitor AT13387;   Radiation: Intensity-Modulated Radiation Therapy;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
23 Recruiting Identification of Prognostic Biomarkers for Progression of Invasive Squamous Cell Carcinoma
Conditions: Carcinoma, Squamous Cell;   Carcinoma, Squamous;   Squamous Cell Carcinoma;   Lung Neoplasms;   Cancer of Lung;   Cancer of the Lung;   Lung Cancer;   Neoplasms, Lung;   Neoplasms, Pulmonary;   Pulmonary Cancer;   Pulmonary Neoplasms
Intervention: Genetic: DNA Extraction
24 Not yet recruiting Cisplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
Conditions: Colorectal Large Cell Neuroendocrine Carcinoma;   Esophageal Large Cell Neuroendocrine Carcinoma;   Gallbladder Large Cell Neuroendocrine Carcinoma;   Gastric Large Cell Neuroendocrine Carcinoma;   Pancreatic Large Cell Neuroendocrine Carcinoma;   Small Intestinal Large Cell Neuroendocrine Carcinoma
Interventions: Drug: Capecitabine;   Drug: Cisplatin;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Drug: Temozolomide
25 Recruiting A Multi-center, Open-label Study of Oral ENMD-2076 for the Treatment of Patients With Advanced Fibrolamellar Carcinoma
Conditions: Advanced Adult Hepatocellular Carcinoma;   Advanced Fibrolamellar Carcinoma
Intervention: Drug: ENMD-2076
26 Unknown  the Efficacy and Safety of Ginsenoside Rg3 Capsule in Prevention of Postoperative Recurrence of Hepatocellular Carcinoma
Conditions: Stage I Hepatocellular Carcinoma;   Stage II Hepatocellular Carcinoma
Interventions: Drug: the ginsenoside Rg3;   Drug: Placebo
27 Unknown  Environmental, Metabolic and Nutritional Factors of Hepatocellular Carcinoma in Cirrhotic Patients
Conditions: Cirrhosis With Hepatocellular Carcinoma;   Cirrhosis Without Hepatocellular Carcinoma
Interventions: Biological: Serum, plasma and DNA samples;   Procedure: Radiological exploration by CT scan or MRI
28 Unknown  Biomarkers Before and After Nephrectomy of Locally Advanced or Metastatic Renal Cell Carcinoma Treated With Everolimus
Conditions: Clear-cell Renal Carcinoma;   Clear-cell Metastatic Renal Cell Carcinoma
Intervention: Drug: Everolimus
29 Recruiting Safety and Tolerability of Everolimus as Second-line Treatment in Poorly Differentiated Neuroendocrine Carcinoma / Neuroendocrine Carcinoma G3 (WHO 2010) and Neuroendocrine Tumor G3 - an Investigator Initiated Phase II Study
Conditions: Poorly Differentiated Neuroendocrine Carcinoma,;   Neuroendocrine Carcinoma, Grade 3;   Neuroendocrine Carcinoma, Grade 1 [Well-differentiated Neuroendocrine Carcinoma] That Switched to G3;   Neuroendocrine Carcinoma, Grade 2 [Moderately Differentiated Neuroendocrine Carcinoma] That Switched to G3;   Neuroendocrine Tumor, Grade 3 and Disease Progression as Measured by Response Evaluation Criteria in Solid Tumors (RECIST 1.1.)
Intervention: Drug: Everolimus (Afinitor®)
30 Recruiting Chemoradiation for Bladder Preservation in Patients With Muscle Invasive Bladder Carcinoma After Complete Response to Neoadjuvant Chemotherapy
Conditions: Bladder Cancer;   Bladder Carcinoma;   Transition Cell Cancer;   Muscle Invasive Bladder Carcinoma
Interventions: Procedure: Transurethral Resection of the Bladder Tumor & Cystoscopy;   Drug: Cisplatin;   Drug: Gemcitabine;   Radiation: Intensity Modulated Radiation Therapy;   Behavioral: Quality of Life Questionnaires;   Genetic: Urine Collection for Molecular Analysis;   Genetic: Blood Collection for Molecular Analysis
31 Recruiting First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma
Conditions: Transitional Cell Carcinoma;   Bladder Carcinoma;   Urothelial Carcinoma
Interventions: Drug: Everolimus;   Drug: Paclitaxel
32 Recruiting Prognostic Role of Primary Non Small Cell Lung Carcinoma Standardized F18-FDG Uptake Values (SUV and TLG) Measured With F18-fluorodeoxyglucose Positron Emission Tomography (F18-FDG-PET): a Non Interventional Study.
Condition: Non Small Cell Lung Carcinoma
33 Recruiting First Line Pazopanib in Poor Risk Patients With Metastatic Renal Cell Carcinoma
Conditions: Locally Advanced and/or Metastatic Renal Cell Carcinoma;   Carcinoma, Renal Cell;   Clear-cell Metastatic Renal Cell Carcinoma
Intervention: Drug: Pazopanib
34 Recruiting Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma
Conditions: Cancer of Head and Neck;   Head and Neck Cancer;   Neoplasms, Head and Neck;   Carcinoma, Squamous Cell of Head and Neck;   Squamous Cell Carcinoma of the Head and Neck;   Squamous Cell Carcinoma, Head and Neck
Interventions: Biological: MK-3475;   Procedure: Surgery;   Radiation: Intensity modulated radiation therapy;   Radiation: Image-guided radiation therapy;   Drug: Cisplatin
35 Recruiting Ph I Vorinostat in the Treatment of Advanced Staged Oropharyngeal Squamous Cell Carcinoma
Conditions: Stage III Squamous Cell Carcinoma of the Oropharynx;   Stage IV Squamous Cell Carcinoma of the Oropharynx
Interventions: Drug: vorinostat;   Drug: cisplatin;   Radiation: radiation therapy;   Procedure: Correlative Studies
36 Recruiting TPF Induction Chemotherapy for Locally Advanced and Resectable Oral Squamous Cell Carcinoma
Conditions: Stage III Oral Cavity Squamous Cell Carcinoma;   Stage IVA Oral Cavity Squamous Cell Carcinoma
Intervention: Drug: TPF induction chemotherapy
37 Recruiting Nivolumab in Treating Patients With Refractory Metastatic Squamous Cell Carcinoma of the Anal Canal
Conditions: Anal Canal Squamous Cell Carcinoma;   Metastatic Anal Canal Carcinoma;   Recurrent Anal Canal Carcinoma
Interventions: Other: Laboratory Biomarker Analysis;   Biological: Nivolumab
38 Recruiting A Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With Small Cell Lung Carcinoma and Other Advanced Cancers
Conditions: Carcinoma Neuroendocrine;   Small Cell Lung Carcinoma;   Malignant Epithelial Neoplasms
Interventions: Drug: Belinostat;   Drug: Cisplatin;   Drug: Etoposide
39 Recruiting A Study of rSIFN-co in Subjects With Advanced Solid Tumors
Conditions: Solid Tumors;   Carcinoma, Non-Small-Cell Lung;   Carcinoma, Renal Cell;   Melanoma;   Carcinoma, Hepatocellular;   Cancer of Colon
Interventions: Drug: rSIFN-co;   Drug: rSIFN-co (Recommended Dose)
40 Recruiting Phase II Sequential and Concurrent Chemoradiation for Advanced Nasopharyngeal Carcinoma (NPC)
Conditions: Stage II Lymphoepithelioma of the Nasopharynx;   Stage II Squamous Cell Carcinoma of the Nasopharynx;   Stage III Lymphoepithelioma of the Nasopharynx;   Stage III Squamous Cell Carcinoma of the Nasopharynx;   Stage IV Lymphoepithelioma of the Nasopharynx;   Stage IV Squamous Cell Carcinoma of the Nasopharynx
Interventions: Drug: docetaxel;   Drug: cisplatin;   Drug: carboplatin;   Drug: fluorouracil;   Radiation: 3-dimensional conformal radiation therapy;   Radiation: intensity-modulated radiation therapy

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years